Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v403-v403 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v403 |
|---|---|
| container_issue | |
| container_start_page | v403 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Cohen, E.E. Hong, D.S. Wise Draper, T. Nassib William, W. Schrijvers, D. Mesia Nin, R. Scott, M.L. Lyne, P. Mugundu, G. McCoon, P. Cook, C.E. Mehta, M.M. Keilholz, U. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx376.001 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx376_001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420384039</els_id><sourcerecordid>S0923753420384039</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1851-e64d43c05ccf10d10916f23246a13a9f08de5cd47b9b9f0aeec86301717a18673</originalsourceid><addsrcrecordid>eNp9UctuFDEQtBBILIEP4NZHIjFZe94jTtESEqSIIBYuXEY9dk_W4LEX27NkP5m_wJPlzMmuVlU_qhh7LfiF4F2xRmudletJPRRNfcG5eMJWoqq7rOWleMpWvMuLrKmK8jl7EcIPznnd5d2K_fm8w0AghnUO2zirI7zZbu6-XG3PAUOgELS9h4AjxeNbiM6Qx0EbvSC0CvaejJ60RX9MOOoszpPzgDLqQyKBG0HN_oBmnnCAvZkDXH5_34mKQ6Klb5X2AG1hj1GTjQF-67gDVAe0khQEZ7SCCY2-t6miKTyODb9mnFxqJskYkOiltm7CZVzcEewI1SPPkvy5HLS5-XT-kj0b0QR69e89Y98-XH3d3GS3d9cfN5e3mRRtJTKqS1UWkldSjoKrZK6ox7zIyxpFgd3IW0WVVGUzdENCSCTbuuCiEQ2Ktm6KMyZOfaV3IXga-73XUzKoF7xfsupPWfWnrPqUVdK8O2koLXbQ5PuQbl0c0J5k7JXT_1H_BWpzoO8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Cohen, E.E. ; Hong, D.S. ; Wise Draper, T. ; Nassib William, W. ; Schrijvers, D. ; Mesia Nin, R. ; Scott, M.L. ; Lyne, P. ; Mugundu, G. ; McCoon, P. ; Cook, C.E. ; Mehta, M.M. ; Keilholz, U.</creator><creatorcontrib>Cohen, E.E. ; Hong, D.S. ; Wise Draper, T. ; Nassib William, W. ; Schrijvers, D. ; Mesia Nin, R. ; Scott, M.L. ; Lyne, P. ; Mugundu, G. ; McCoon, P. ; Cook, C.E. ; Mehta, M.M. ; Keilholz, U.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx376.001</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v403-v403</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1851-e64d43c05ccf10d10916f23246a13a9f08de5cd47b9b9f0aeec86301717a18673</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Cohen, E.E.</creatorcontrib><creatorcontrib>Hong, D.S.</creatorcontrib><creatorcontrib>Wise Draper, T.</creatorcontrib><creatorcontrib>Nassib William, W.</creatorcontrib><creatorcontrib>Schrijvers, D.</creatorcontrib><creatorcontrib>Mesia Nin, R.</creatorcontrib><creatorcontrib>Scott, M.L.</creatorcontrib><creatorcontrib>Lyne, P.</creatorcontrib><creatorcontrib>Mugundu, G.</creatorcontrib><creatorcontrib>McCoon, P.</creatorcontrib><creatorcontrib>Cook, C.E.</creatorcontrib><creatorcontrib>Mehta, M.M.</creatorcontrib><creatorcontrib>Keilholz, U.</creatorcontrib><title>Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9UctuFDEQtBBILIEP4NZHIjFZe94jTtESEqSIIBYuXEY9dk_W4LEX27NkP5m_wJPlzMmuVlU_qhh7LfiF4F2xRmudletJPRRNfcG5eMJWoqq7rOWleMpWvMuLrKmK8jl7EcIPznnd5d2K_fm8w0AghnUO2zirI7zZbu6-XG3PAUOgELS9h4AjxeNbiM6Qx0EbvSC0CvaejJ60RX9MOOoszpPzgDLqQyKBG0HN_oBmnnCAvZkDXH5_34mKQ6Klb5X2AG1hj1GTjQF-67gDVAe0khQEZ7SCCY2-t6miKTyODb9mnFxqJskYkOiltm7CZVzcEewI1SPPkvy5HLS5-XT-kj0b0QR69e89Y98-XH3d3GS3d9cfN5e3mRRtJTKqS1UWkldSjoKrZK6ox7zIyxpFgd3IW0WVVGUzdENCSCTbuuCiEQ2Ktm6KMyZOfaV3IXga-73XUzKoF7xfsupPWfWnrPqUVdK8O2koLXbQ5PuQbl0c0J5k7JXT_1H_BWpzoO8</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Cohen, E.E.</creator><creator>Hong, D.S.</creator><creator>Wise Draper, T.</creator><creator>Nassib William, W.</creator><creator>Schrijvers, D.</creator><creator>Mesia Nin, R.</creator><creator>Scott, M.L.</creator><creator>Lyne, P.</creator><creator>Mugundu, G.</creator><creator>McCoon, P.</creator><creator>Cook, C.E.</creator><creator>Mehta, M.M.</creator><creator>Keilholz, U.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)</title><author>Cohen, E.E. ; Hong, D.S. ; Wise Draper, T. ; Nassib William, W. ; Schrijvers, D. ; Mesia Nin, R. ; Scott, M.L. ; Lyne, P. ; Mugundu, G. ; McCoon, P. ; Cook, C.E. ; Mehta, M.M. ; Keilholz, U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1851-e64d43c05ccf10d10916f23246a13a9f08de5cd47b9b9f0aeec86301717a18673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, E.E.</creatorcontrib><creatorcontrib>Hong, D.S.</creatorcontrib><creatorcontrib>Wise Draper, T.</creatorcontrib><creatorcontrib>Nassib William, W.</creatorcontrib><creatorcontrib>Schrijvers, D.</creatorcontrib><creatorcontrib>Mesia Nin, R.</creatorcontrib><creatorcontrib>Scott, M.L.</creatorcontrib><creatorcontrib>Lyne, P.</creatorcontrib><creatorcontrib>Mugundu, G.</creatorcontrib><creatorcontrib>McCoon, P.</creatorcontrib><creatorcontrib>Cook, C.E.</creatorcontrib><creatorcontrib>Mehta, M.M.</creatorcontrib><creatorcontrib>Keilholz, U.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, E.E.</au><au>Hong, D.S.</au><au>Wise Draper, T.</au><au>Nassib William, W.</au><au>Schrijvers, D.</au><au>Mesia Nin, R.</au><au>Scott, M.L.</au><au>Lyne, P.</au><au>Mugundu, G.</au><au>McCoon, P.</au><au>Cook, C.E.</au><au>Mehta, M.M.</au><au>Keilholz, U.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v403</spage><epage>v403</epage><pages>v403-v403</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx376.001</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v403-v403 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx376_001 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T00%3A58%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%201b/2%20Study%20(SCORES)%20assessing%20safety,%20tolerability,%20and%20preliminary%20anti-tumor%20activity%20of%20durvalumab%20plus%20AZD9150%20or%20AZD5069%20in%20patients%20with%20advanced%20solid%20malignancies%20and%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20(SCCHN)&rft.jtitle=Annals%20of%20oncology&rft.au=Cohen,%20E.E.&rft.date=2017-09&rft.volume=28&rft.spage=v403&rft.epage=v403&rft.pages=v403-v403&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx376.001&rft_dat=%3Celsevier_cross%3ES0923753420384039%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420384039&rfr_iscdi=true |